Skip to main content
EuroGCT
Menu
Close
Help and support
Help and support
FAQ's
Glossary
FAQ's
How is the safety of a new gene therapy determined?
How are gene and cell therapies different to 'traditional' therapies?
Where do embryonic stem cells for research come from?
How is the production of gene and cell therapies different to traditional treatments?
Why do we need gene and cell therapies? How are they different from traditional medicines and treatments?
What is genetic testing?
Is it ethical to use animals in health and scientific research?
What are the roles of regulators in the development of gene and cell therapies?
See all FAQs
Glossary
Accelerated assessment
Adeno-associated virus (AAV)
Adenovirus
Adult stem cells
Advanced Therapy Investigational Medicinal Product (ATIMP)
Advanced Therapy Medicinal Product (ATMP)
Advertising
Antibody
See full Glossary
Search
Select language
Select language
English
Français
Deutsch
Italiano
Polski
Español
Português
Select language
Select language
English
Français
Deutsch
Italiano
Polski
Español
Português
Condition
Muscle and Skeletal Diseases
Blood Disorders
Sickle Cell Disease
Cardiovascular Disease
Heart Disease
Stroke
Bowel Disease
Cancer
Cystic Fibrosis
Eye Disease
Immune Conditions
Diabetes
Immune Deficiency
Multiple Sclerosis
Kidney Disease
Liver Disease
Lung Disease
Bone and Muscle Conditions
Muscular Dystrophy
Spinal Cord Injuries
Neurological Disorders
Alzheimer's Disease
Cerebral Palsy
Huntington's Disease
Motor Neurone Disease
Parkinson's Disease
Spinal Muscular Atrophy
Skin
Epidermolysis Bullosa
Reproduction and Fertility
Theme
Cell and Gene Fundamentals
Blood Stem Cells
Genes and Inheritance
Cord Blood
Embryonic Stem Cells
iPS cells
MSCs
Skin Stem Cells
Current and Potential Uses
Cell Therapy
Gene Therapy
Clinical Trials
CAR-T Therapy
Methods and Tools
Disease Modelling
Organoids
Tissue Engineering
Gene Editing
Reprogramming
Ethics and Society
Patient Involvement
Policy & Regulation
Unproven Treatments
Main navigation
Discover
Discover
Educational Resources Directory
INTENS
LEARN
Research Pathways
Research Pathways
EuroGCT Key Resources
ATMP Engage
CARTALLEU
Actors and Network database
Law, Policy and Social License for Regenerative Medicine
About Us
Contact
Breadcrumb
Home
In the Spotlight: Is banking cord blood a good investment?
Resources
Search within the page or choose from the most common topics below
Theme
Cell and Gene Fundamentals
Blood Stem Cells
Cell Therapy
Patient Involvement
Disease Modelling
Gene Therapy
Genes and Inheritance
Policy & Regulation
Organoids
Spotlight on Research
Clinical Trials
Cord Blood
Tissue Engineering
Unproven Treatments
CAR-T Therapy
Embryonic Stem Cells
Gene Editing
iPS cells
Reprogramming
MSCs
Skin Stem Cells
Current and Potential Uses
Methods and Tools
Ethics and Society
Research
Stem Cell News
Factsheets
Industry
Explore Stem Cells
Condition
Sickle Cell Disease
Alzheimer's Disease
Heart Disease
Diabetes
Muscular Dystrophy
Epidermolysis Bullosa
Stroke
Cerebral Palsy
Immune Deficiency
Spinal Cord Injuries
Huntington's Disease
Multiple Sclerosis
Motor Neurone Disease
Muscle and Skeletal Diseases
Parkinson's Disease
Spinal Muscular Atrophy
Blood Disorders
Cardiovascular Disease
Bowel Disease
Cancer
Cystic Fibrosis
Eye Disease
Immune Conditions
Kidney Disease
Liver Disease
Lung Disease
Bone and Muscle Conditions
Neurological Disorders
Skin
Reproduction and Fertility
Cord Blood
Rare Diseases
Search by keyword
EuroGCT Resource
Gene Horizons: Film and Toolkit
Related Topics
Sickle Cell Disease
Cancer
Immune Conditions
Cell and Gene Fundamentals
Genes and Inheritance
Current and Potential Uses
Gene Therapy
CAR-T Therapy
Gene Editing
EuroGCT Resource
[Poster] The challenges of Advanced Therapy Medicinal Products manufacturing in the European Union: Strengths and limits of current regulatory tools
EuroGCT Resource
Why are some conditions more suitable for gene and cell therapies than others?
Related Topics
Current and Potential Uses
Cell Therapy
Gene Therapy
Clinical Trials
Methods and Tools
Disease Modelling
Gene Editing
Ethics and Society
Patient Involvement
Policy & Regulation
EuroGCT Resource
Where should I start?
Related Topics
Cell and Gene Fundamentals
Cell Therapy
Clinical Trials
Current and Potential Uses
Ethics and Society
Factsheets
Gene Therapy
Methods and Tools
Patient Involvement
Policy & Regulation
EMA certification procedures for SMEs
English
EuroGCT Resource
Using 'reprogrammed' cells to model diseases
Related Topics
iPS cells
Current and Potential Uses
Methods and Tools
Disease Modelling
Organoids
Tissue Engineering
Reprogramming
EuroGCT Resource
There is an approved treatment for my condition - why can't I receive it?
Related Topics
Rare Diseases
Current and Potential Uses
Clinical Trials
Ethics and Society
Policy & Regulation
Unproven Treatments
Industry
ATTC Advanced Therapies NHS Readiness Toolkit
EMA Resource: Journey of a Medicine
Gene Horizons: Classroom Quiz
Support for ATMPs development in Spain: the (central) role of the Spanish Medicines Agency (AEMPS)
The 2022 French Strategy on biotherapies and bioproduction of advanced therapies: results after 3 years launch and perspectives
European Union policies and their impact on ATMP Research and Innovation
Policy and regulatory strategies: current and prospective impact on gene and cell therapy development
Potential gene therapies for cystic fibrosis: a plain language summary
Related Topics
Cystic Fibrosis
Current and Potential Uses
Gene Therapy
EuroGCT Resource
Deciphering Diabetes with Human Blood Vessels from Stem Cells
Related Topics
Diabetes
Current and Potential Uses
Short introduction the Health Technology Assessment Regulation
Health technology assessment for academic ATMPs
Equitable access to ATMPs in the Netherlands: Impact of the EU regulation and the BENELUXA initiative on HTA
EuroStemCell Resource
Video: Sporty Stem Cells - how stem cells can help cartilage injury
Related Topics
Bone and Muscle Conditions
Current and Potential Uses
Pagination
Page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next ›
Last page
Last »